ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback